Therapeutic regimens in interstitial lung disease guided by genetic screening: fact or fiction?

D rug-induced pulmonary toxicity is a serious and expanding problem [1, 2]. Since the mid 1980s, the understanding of the metabolism of pharmaceuticals has increased substantially. Not least because of the introduction of molecular biological techniques, defects in drug-metabolising pathways have been elucidated. Nowadays, pharmacogenetics can guide the clinician in the choice of the best therapeutic regimen, resulting in ‘‘personalised medicine’’ [3].